HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
George Fountzilas(Aristotle University of Thessaloniki), P. Arapantoni(Metaxa Hospital)
Cited by 100
Related Papers
Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group
|Journal of Translational Medicine|2017|22
Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab
|Cancer Genomics & Proteomics|2018|17
Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy
|Cancer Genomics & Proteomics|2020|5